"Cyclopentanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of alicyclic hydrocarbons with the general formula R-C5H9.
| Descriptor ID |
D003517
|
| MeSH Number(s) |
D02.455.426.392.368.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclopentanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclopentanes".
This graph shows the total number of publications written about "Cyclopentanes" by people in this website by year, and whether "Cyclopentanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclopentanes" by people in Profiles.
-
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672.
-
The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12).
-
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
-
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20528-20538.
-
Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme. Structure. 2017 07 05; 25(7):1120-1129.e3.
-
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Mol Cancer Ther. 2017 08; 16(8):1693-1704.
-
Antiviral therapy for respiratory viral infections in immunocompromised patients. Expert Rev Anti Infect Ther. 2017 04; 15(4):401-415.
-
LRRC8A channels support TNFa-induced superoxide production by Nox1 which is required for receptor endocytosis. Free Radic Biol Med. 2016 12; 101:413-423.
-
Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett. 2017 01 28; 385:207-214.